Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the "E ...

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the "E ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer Kristen Buck – Executive Vice President-Research and Development and Chief Medical Officer James Nisco – Chief Accounting Officer Conference Call Participants Sara Nik – H.C. Wainwright Will Hidell – Brookline Capital Markets Pete Enderlin – MAZ Partners Steve Bro ...

Appendix Dose on days 1, 8, 15 every 28 days INTERVENTION Arm (N=20) • Nab-paclitaxel 125 mg/m2 IV • Matching certepetide Placebo IV • Gemcitabine 1000 mg/m2 IV • Matching Placebo certepetide IV 4 hours later • Timing: Enrollment completed December 2023; Earliest possible data 2024 Phase 2b randomized, doubleblind study in mPDAC testing gemcitabine + nab-paclitaxel (SoC) with two certepetide dose regimens or placebo Sponsor/Partner ▪ Qilu Pharmaceutical (funds all development in China) ▪ Primary: AEs, SAEs, ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subj ...

Exhibit 99.1 Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, NJ (May 9, 2024) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious dise ...

BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for three months ended March 31, 2024, on Thursday, May 9, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate ...

BASKING RIDGE, N.J. and JINAN, China, April 23, 2024 (GLOBE NEWSWIRE) --  Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Qilu Pharmaceutical Co., Ltd. ("Qilu"), one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished products and active pharmaceutical ingredients, ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants John Menditto - VP, Investor Relations & Corporate Communications James Nisco - VP, Finance & Treasury David Mazzo - President, CEO & Director Kristen Buck - EVP, Research & Development & Chief Medical Officer Conference Call Participants Sara Nik - H.C. Wainwright & Co. Peter Enderlin - MAZ Capital Advisors Kemp Dolliver - Brookline Capital Markets Operator Welcome to the Lisata Therap ...